person · Reporting owner
Henderson Jeffrey William
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BECTON DICKINSON & COBDX · Entity 2498 | Director | January 27, 2026 | January 29, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | May 05, 2026 | May 07, 2026 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | September 01, 2023 | September 07, 2023 |
| QUALCOMM INC/DEQCOM · Entity 2852 | Director | March 17, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BECTON DICKINSON & CO
Report date January 27, 2026 · Filed January 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,143 |
Reported balance
After 2026-01-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 1,098 · Balance 9,143 F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2: Includes units acquired through dividend investment since the last report filed by the reporting person. |
| Common StockSEC Table I · non-derivative | IndirectBy wife | 15 |
Reported balance
Holding disclosure · report date 2026-01-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.
F2: Includes units acquired through dividend investment since the last report filed by the reporting person.
HALOZYME THERAPEUTICS, INC.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,572 |
Reported balance
After 2026-05-05 transaction · row 1
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 3,796 · Balance 36,572 F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $65.87 · Expires 2036-05-05 | Direct | 6,040 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 6,040 · Balance 6,040 F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.
F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.
KYNTRA BIO, INC.
Report date September 01, 2023 · Filed September 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,866 |
Reported balance
After 2023-09-01 transaction · row 1
1 source rowRow 1 · 2023-09-01 · Sale · Disposed 2,000 · Balance 28,866 F1: Shares sold by the reporting person pursuant to a 10b5-1 trading plan dated March 3, 2023. F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.970 to $1.075. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold by the reporting person pursuant to a 10b5-1 trading plan dated March 3, 2023.
F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.970 to $1.075. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
QUALCOMM INC/DE
Report date March 17, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,598.6901 |
Reported balance
After 2026-03-17 transaction · row 1
1 source rowRow 1 · 2026-03-17 · Grant · Acquired 2,563 · Balance 14,598.6901 F1: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2026 Director Compensation Plan. Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) March 17, 2029 (2) death, (3) disability, or (4) a change in control. If an election is made to settle the units partially in cash, such partial cash settlement will be reported on a subsequent Form 4 (if applicable) as a disposition to the Issuer on the settlement date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2026 Director Compensation Plan. Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) March 17, 2029 (2) death, (3) disability, or (4) a change in control. If an election is made to settle the units partially in cash, such partial cash settlement will be reported on a subsequent Form 4 (if applicable) as a disposition to the Issuer on the settlement date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed May 7, 2026 23:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 6,040 | $0.00 Strike: $65.87 | $0.00 |
DisclosureSEC source: 0001159036-26-000061 · wk-form4_1778194968.xml · derivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,040 Underlying: Common Stock · 6,040 shares Expires 2036-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2026 Filed May 7, 2026 23:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 3,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000061 · wk-form4_1778194968.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,572 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 22:07 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | GrantCommon Stock | 2,563 | $0.00 | $0.00 |
DisclosureSEC source: 0000804328-26-000038 · edgardoc.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,598.6901 F1 · shares: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2026 Director Compensation Plan. Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) March 17, 2029 (2) death, (3) disability, or (4) a change in control. If an election is made to settle the units partially in cash, such partial cash settlement will be reported on a subsequent Form 4 (if applicable) as a disposition to the Issuer on the settlement date. Read SEC document |
| March 08, 2026 Filed Mar 9, 2026 20:49 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Exercise / conversionDeferred Stock Unit · Derivative | 2,355.1987 | $0.00 | $0.00 |
DisclosureSEC source: 0000804328-26-000025 · edgardoc.xml · derivative · entry 3 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,683.1728 Underlying: Common Stock · 2,355.1987 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock. F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. Read SEC document |
| March 08, 2026 Filed Mar 9, 2026 20:49 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Disposition to issuerCommon Stock | 759 | $135.69 | $102,988.71 |
DisclosureSEC source: 0000804328-26-000025 · edgardoc.xml · nonDerivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,035.6901 Read SEC document |
| March 08, 2026 Filed Mar 9, 2026 20:49 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Exercise / conversionCommon Stock | 2,355 | $0.00 | $0.00 |
DisclosureSEC source: 0000804328-26-000025 · edgardoc.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,794.6901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of Annual Deferred Stock Units granted to the recipient on March 8, 2023. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 14:58 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-004019 · wk-form4_1769698710.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,143 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 5,750 | $0.00 Strike: $60.03 | $0.00 |
DisclosureSEC source: 0001415889-25-011771 · form4-05022025_080526.xml · derivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2035-05-01 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 4,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011771 · form4-05022025_080526.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,776 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 28, 2025 Filed Apr 28, 2025 22:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 200 | $61.00 | $12,199.00 |
DisclosureSEC source: 0001415889-25-011432 · form4-04282025_100414.xml · nonDerivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,611 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $60.97 to $61.02. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 28, 2025 Filed Apr 28, 2025 22:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,297 | $60.34 | $259,268.09 |
DisclosureSEC source: 0001415889-25-011432 · form4-04282025_100414.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,811 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $59.93 to $60.69. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 01, 2025 Filed Apr 1, 2025 22:32 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 503 | $64.05 | $32,217.15 |
DisclosureSEC source: 0001415889-25-009440 · form4-04012025_100413.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,108 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 20:19 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | GrantCommon Stock | 2,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-25-000025 · edgardoc.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,406 F1 · shares: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2025 Director Compensation Plan. Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) March 18, 2028 (2) death, (3) disability, or (4) a change in control. If an election is made to settle the units partially in cash, such partial cash settlement will be reported on a subsequent Form 4 (if applicable) as a disposition to the Issuer on the settlement date. Read SEC document |
| March 09, 2025 Filed Mar 10, 2025 20:30 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Exercise / conversionDeferred Stock Unit · Derivative | 1,901.0354 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-25-000015 · edgardoc.xml · derivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,938.3647 Underlying: Common Stock · 1,901.0354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock. F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. Read SEC document |
| March 09, 2025 Filed Mar 10, 2025 20:30 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Exercise / conversionCommon Stock | 1,901 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-25-000015 · edgardoc.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of Annual Deferred Stock Units granted to the recipient on March 9, 2022. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 01:46 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 3,205 | $59.12 | $189,466.78 |
DisclosureSEC source: 0001415889-25-006323 · form4-03042025_010322.xml · nonDerivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,611 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $58.80 to $59.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 01:46 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,795 | $57.93 | $103,991.53 |
DisclosureSEC source: 0001415889-25-006323 · form4-03042025_010322.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,816 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.73 to $58.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2025 Filed Feb 10, 2025 22:03 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | PurchaseCommon Stock | 1,500 | $233.62 | $350,430.00 |
DisclosureSEC source: 0001062993-25-001977 · form4.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,015 Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 23:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 3,900 | $56.41 | $219,979.50 |
DisclosureSEC source: 0001415889-25-003006 · form4-02042025_110227.xml · nonDerivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,611 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.22 to $56.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 23:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,100 | $55.94 | $61,537.30 |
DisclosureSEC source: 0001415889-25-003006 · form4-02042025_110227.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,511 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.22 to $56.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 21:00 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001300 · form4.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,515 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $50.01 | $500,060.00 |
DisclosureSEC source: 0001415889-25-000995 · form4-01072025_090159.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,611 F1 · kind: The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on September 17, 2024 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.00 to $50.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 21:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 8,804 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0001415889-24-011685 · form4-04292024_090447.xml · derivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,804 Underlying: Common Stock · 8,804 shares Expires 2034-04-25 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 21:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 6,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011685 · form4-04292024_090447.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,611 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| March 10, 2024 Filed Mar 11, 2024 21:09 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Exercise / conversionDeferred Stock Unit · Derivative | 2,056.6383 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-24-000029 · edgardoc.xml · derivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,726.0743 Underlying: Common Stock · 2,056.6383 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock. F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. Read SEC document |
| March 10, 2024 Filed Mar 11, 2024 21:09 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Exercise / conversionCommon Stock | 2,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-24-000029 · edgardoc.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of Annual Deferred Stock Units granted to the recipient on March 10, 2021. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 21:44 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | GrantDeferred Stock Unit · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-24-000019 · edgardoc.xml · derivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,772.338 Underlying: Common Stock · 1,624 shares Expires not disclosed F1 · security: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2024 Director Compensation Plan. F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock. F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:17 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001307 · form4.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,568 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| September 01, 2023 Filed Sep 7, 2023 00:54 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $1.03 | $2,060.00 |
DisclosureSEC source: 0001209191-23-048554 · doc4.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,866 F1 · shares: Shares sold by the reporting person pursuant to a 10b5-1 trading plan dated March 3, 2023. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $0.970 to $1.075. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 23:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $1.91 | $3,820.00 |
DisclosureSEC source: 0001209191-23-045087 · doc4.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,866 F1 · shares: Shares sold by the reporting person pursuant to a 10b5-1 trading plan dated March 3, 2023. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $1.865 to $1.925. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 11, 2023 Filed Jul 14, 2023 00:28 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,000 | $2.69 | $5,380.00 |
DisclosureSEC source: 0001209191-23-042247 · doc4.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,866 F1 · shares: Shares sold by the reporting person pursuant to a 10b5-1 trading plan. F2 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $2.66 to $2.735. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 23:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,994 | $17.69 | $88,343.86 |
DisclosureSEC source: 0001209191-23-036074 · doc4.xml · nonDerivative · entry 3 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,866 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F4 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.52 to $17.86. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 23:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,006 | $16.87 | $33,841.22 |
DisclosureSEC source: 0001209191-23-036074 · doc4.xml · nonDerivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,860 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F3 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.52 to $17.51. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 23:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 12,666 | $0.00 Strike: $17.13 | $0.00 |
DisclosureSEC source: 0001209191-23-036074 · doc4.xml · derivative · entry 4 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,666 Underlying: Common Stock · 12,666 shares Expires 2033-06-06 F5 · derivative.exercise_date: Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 23:52 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 8,289 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036074 · doc4.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,866 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 11,371 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007691 · form4-05092023_100551.xml · derivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,371 Underlying: Common Stock · 11,371 shares Expires 2033-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007691 · form4-05092023_100551.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,110 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 22:47 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Exercise / conversionDeferred Stock Unit · Derivative | 3,316.6108 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-23-000026 · edgardoc.xml · derivative · entry 3 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,004.412 Underlying: Common Stock · 3,316.6108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock. F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 22:47 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Disposition to issuerCommon Stock | 1,069 | $115.19 | $123,138.11 |
DisclosureSEC source: 0001888316-23-000026 · edgardoc.xml · nonDerivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,352 Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 22:47 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Exercise / conversionCommon Stock | 3,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-23-000026 · edgardoc.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the settlement of Annual Deferred Stock Units granted to the recipient on March 10, 2020. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 21:24 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | GrantDeferred Stock Unit · Derivative | 2,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-23-000016 · edgardoc.xml · derivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,301.048 Underlying: Common Stock · 2,203 shares Expires not disclosed F1 · security: Represents the grant of Annual Deferred Stock Units to Directors pursuant to the Qualcomm Incorporated 2023 Director Compensation Plan. F2 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock. F3 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. F3 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. Read SEC document |
| March 01, 2023 Filed Mar 1, 2023 23:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $47.71 | $477,100.00 |
DisclosureSEC source: 0001415889-23-003703 · form4-03012023_110312.xml · nonDerivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,045 Read SEC document |
| February 28, 2023 Filed Mar 1, 2023 23:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $48.51 | $485,100.00 |
DisclosureSEC source: 0001415889-23-003703 · form4-03012023_110312.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,045 Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 21:08 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | SaleCommon Stock | 2,500 | $124.19 | $310,468.50 |
DisclosureSEC source: 0001888316-23-000008 · edgardoc.xml · nonDerivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,105 F2 · price: The sale prices for this transaction ranged from $124.08 to $124.36 The filer hereby agrees to provide, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:08 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | SaleCommon Stock | 2,500 | $124.05 | $310,132.25 |
DisclosureSEC source: 0001888316-23-000008 · edgardoc.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,605 F1 · price: The sale prices for this transaction ranged from $123.94 to $124.20 The filer hereby agrees to provide, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 23:06 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 848 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-001435 · form4.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,653 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:12 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 25,684 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038613 · doc4.xml · derivative · entry 2 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,684 Underlying: Common Stock · 25,684 shares Expires 2032-06-15 F2 · derivative.exercise_date: Options vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:12 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 15,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038613 · doc4.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,577 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 05, 2022 Filed May 7, 2022 00:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units | 6,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002909 · edgar.xml · nonDerivative · entry 1 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,045 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| March 12, 2022 Filed Mar 15, 2022 20:08 UTC | QUALCOMM INC/DE QCOM · Entity 2852 | Exercise / conversionDeferred Stock Unit · Derivative | 4,559.8255 | $0.00 | $0.00 |
DisclosureSEC source: 0001888316-22-000022 · edgardoc.xml · derivative · entry 3 Henderson Jeffrey William · CIK 0001324015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,944.4914 Underlying: Common Stock · 4,559.8255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Deferred Stock Unit represents a right to receive one share of the Company's common stock. F2 · derivative.exercise_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. F2 · derivative.expiration_date: Deferred Stock Units are 100% vested on the grant date. The units will be settled in shares of the Company's common stock (and partially in cash if election is made within 60 days of the date of grant) in accordance with the grant agreement on the earlier of (1) third anniversary of the date of grant, (2) death, (3) disability, or (4) a change in control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.